DUBLIN, Nov. 26, 2014
/PRNewswire/ -- Research and Markets has announced the addition of the "Microneedles for Trans / Intradermal Drug Delivery" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769
Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology. The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine - device combination products (referred to as products hereafter) in clinical trials. During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters. The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030' report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION TO MICRONEEDLES 4. MARKET OVERVIEW 5. TECHNOLOGY PROVIDERS 6. ACADEMIA 7. PRODUCT PROFILES 8. CASE STUDIES 9. MARKET FORECAST, 2014-2030 10. SWOT ANALYSIS 11. INTERVIEW TRANSCRIPTS 12. CONCLUSION13. APPENDIX 1: TABULATED DATA 14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS Companies Mentioned:
Media Contact:
Laura Wood , +353-1-481-1716, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/microneedles-for-trans--intradermal-drug-delivery-300001563.html
SOURCE Research and Markets
Advertisement
Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology. The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine - device combination products (referred to as products hereafter) in clinical trials. During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters. The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030' report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION TO MICRONEEDLES 4. MARKET OVERVIEW 5. TECHNOLOGY PROVIDERS 6. ACADEMIA 7. PRODUCT PROFILES 8. CASE STUDIES 9. MARKET FORECAST, 2014-2030 10. SWOT ANALYSIS 11. INTERVIEW TRANSCRIPTS 12. CONCLUSION13. APPENDIX 1: TABULATED DATA 14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS Companies Mentioned:
Advertisement
- 10X Technology
- 3M Drug Delivery Systems
- 3M Unitek
- 4P Therapeutics
- AAC
- AKM
- Abingworth
- Advanced Technology Ventures
- Agate Medical Investments
- AllTranz
- Alza Corporation
- Amspar B.V
- Analog Devices
- Angiomed
- Aphelion Capital
- Apogee Technology
- Asahi Kasei Pharma Corporation (AKP)
- AvagoTechnologies
- BB Biotech Ventures
- Bausch & Lomb
- Becton Dickinson
- Biacore
- BioMed Ventures
- BioSerenTach
- Biochemics
- Biotech Growth N.V
- Bosch
- Brandon Capital
- Brookside Capital
- CEA-LETI
- CHL Medical Partners
- Canon
- Capital Royalty L.P
- Carrera
- Cerametal
- Circassia
- Clearside Biomedical
- Corium International
- Curasen
- D-Partners
- Debiotech
- Denso
- Elcam Medical
- Enterprise Ireland
- Essex Woodlands Health Ventures
- Extraject Technologies
- F2 Biosciences III, L.P.
- Flir Systems
- FluGen
- Forma Medical
- Fraunhofer Institute
- Freescale Semiconductor
- Fujifilm
- GE Sensing
- GSK
- Georgia Research Alliance Venture Fund
- HBM BioVentures
- HBM Partners
- HLM Venture Partners
- Hatteras Venture Partners
- HealthCare Ventures
- Hewlett Packard
- Honeywell
- IBM
- ImmuPatch
- Infineon Technologies
- Invensense
- Ipsen Pharma
- Iscar
- Israel HealthCare Ventures (IHCV)
- Janisys
- Janssen Pharmaceuticals
- Kaiser Permanente Ventures
- Kenan Flagler Business School Private Equity Fund
- Kionix
- Knowles Electronics
- Knox LLC
- Lexmark
- Lonza Group Ltd.
- MPM Capital
- Macroflux Corporation
- Measurement Specialities Inc.
- Mecaplast
- Medicago
- Memsic
- Mercatus Capital and GITP (Global Innovations & Technology Platform) Investments
- Merck
- Metalor Dental
- MicroCreate B.V
- Micropoint Technologies
- Mountain Group Capital
- Murata
- Nanopass
- Nemaura Pharma
- New Enterprise Associates (NEA)
- Nissha Printing Co. Ltd
- Nomura Phase4 Ventures
- Novartis
- Novo Nordisk
- Novosanis
- ONSET Ventures
- Ofer Hi-Tech
- Omron
- OneVentures
- Oxford NanoDelivery
- PKA SoftTouch Corp
- Panasonic
- Par Pharmaceuticals
- Philips Medisize
- Phillips Plastic Corporation
- Phonak AG
- Pitango Venture Capital
- Pro-micron
- ProQuest Investments
- Procter & Gamble
- Quantum Technology Partners
- Radius Health
- Robert Bosch
- Rolex
- RusanoMedInvest (RMI)
- ST Microelectronics
- Sanofi Pasteur
- Santen Inc.
- Seco
- Seiko Epson
- Sensata
- Sony
- Star Surgical
- StrataGent Life Sciences
- TechnoPhage
- Teva Pharmaceuticals
- Texas Instruments
- TheraJect
- TransDerm Inc.
- Triquint
- Tyco Electronics
- UTC Aerospace
- Ulis
- Valeritas
- Vaxxas
- WFD Ventures
- Welsh, Carson, Anderson & Stowe (WCAS)
- Zosano Pharma
- nanoBioSciences
Media Contact:
Laura Wood , +353-1-481-1716, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/microneedles-for-trans--intradermal-drug-delivery-300001563.html
SOURCE Research and Markets
